Minerva Neurosciences - $6.05

We wrote about Minerva Neursciences  (NERV) when they were just completing some important corporate goals in anticipation of upcoming clinical trials. The lead drug is MIN-101 for negative symptoms of Schizophrenia, which is scheduled to start a 500 patient study soon. Patients will be recruited throughout Europe, with 30% of participants coming from the US. Currently there is not an FDA approved drug for negative symptoms of Schizophrenia, so this fits into our category of an unmet medical need. The phase 2 clinical trial with MIN-101 proved to be effective. The results of that clinical trial are below.
 
PANSS Negative Symptom Score at 12 Weeks

• 32mg  p = 0.021    effect size   .45
• 64mg  p = 0.003   effect size .  58

The 500 patient phase 3 study is to determine if MIN-101 is effective again, for the negative symptoms of Schizophrenia. The patent for MIN-101 extends out to 2035. Thank you for reading.